Associate Professor Nuala Ann Helsby

BSc(Hons), PhD

Research | Current

"Understanding the inherited differences between individuals may help us improve the safe and effective use of medications and other therapies”.

How do your genes influence drug disposition?

Some people can respond well and others may have substantial side effects when given the same medication. Numerous factors affect how the body handles a drug, but one reason is the inherited differences in the expression of drug metabolising enzymes or drug transporters - this is known as pharmacogenetics. There has been a lot of optimism that sequencing the human genome will allow tailored selection of the appropriate drug at the right dose for each individual patient. However, many of the genes important in drug disposition are readily up- and down-regulated by either disease processes, the co-administration of other drugs and even dietary changes. Understanding gene expression and epigenetic regulation (pharmacogenomics) is an important and often overlooked component of “personalised medicine”.

Much of my research focusses on the pharmacogenomics of common cancer medications, because of the very narrow window between a safe and effective dose and life-threatening side effects. I also have an interest in how genomics may predict chronic pain after breast cancer surgery as well as the role of pharmacogenomics in treatments for autoimmune disease.

To do this type of research we need to determine an individual’s genetic make-up, to understand the complex processes underpinning drug disposition, accurately quantify drug levels in a patients and also have clinical information about patient outcomes. This requires strong links between the laboratory and clinicians. We have expertise in measuring drugs and their metabolites using analytical techniques such as LC/MS, genomics and design of clinical trials.

My research group includes:

Dr Kathryn Burns (John Gavin Postdoctoral Research Fellow; Genesis Oncology Trust)

Dr Soo Hee Jeong

Umaiyaall Shanmugaraajah, research technician

as well as postgraduate research students.

 

Postgraduate supervision

Current supervision

  • Daniel Chiang (PhD candidate)
  • Maia van Kan (PhD candidate)
  • Minghan Yong  (BBiomedSc(Hons) candidate)

Co-supervision with Dr Kathryn Burns

  • Mayerni Situmorang (MSc candidate)

    

Distinctions/Honours

  • International Union of Basic and Clinical Pharmacology (IUPHAR). Councillor on the executive board of the Drug Metabolism and Drug Transporter section (2014-2018), Vice-chair (2018-2022)
  • Member of council Australasian Society of Clinical Experimental Pharmacology and Toxicology (ASCEPT)
  • Chair of ASCEPT-NZ section (2017-2019)
    • Secretary of ASCEPT-NZ (Nov 2011-2014)
    • NZ representative on the ASCEPT Pharmacogenetics Interest Group Committee (2007-present)
  • Member of British Pharmacology Society (BPS)
  • Member of NZ Society of Oncologists

 

 

Responsibilities

  • Executive editor of the British Journal of Clinical Pharmacology
  • Review editor for Frontiers in Pharmacogenetics and Pharmacogenomics (2011-present)
  • Ad hoc reviewer for the international journals: Clinical Pharmacokinetics, Molecular Pharmaceutics and Special issue of Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Chemico-Biological Interactions, Cancer Gene Therapy, British Journal of Clinical Pharmacology, Environmental Toxicology and Pharmacology, Drug Metabolism and Drug Interactions, Cancer Chemotherapy and Pharmacology, Australian Medical Student Journal, European Journal of Drug Metabolism and Pharmacokinetics
  • Invited member of the reviewer panel for Current Drug Metabolism and  Drug Metabolism Letters  (2012-2014)

Areas of expertise

Pharmacogenetics, human pharmacology, biotransformation, transporters and cancer drugs

Committees/Professional groups/Services

Member

  • British Pharmacology Society
  • Australasian Society of Clinical and Experimental Pharmacology
  • New Zealand Society for Oncology

Selected publications and creative works (Research Outputs)

  • Tucci, J. D., Pumuye, P. P., Helsby, N. A., Barratt, D. T., Pokeya, P. P., Hombhanje, F., & Somogyi, A. A. (2018). Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and genomics, 28 (6), 153-164. 10.1097/fpc.0000000000000335
  • Burns, K. E., Lo, W. Y., Findlay, M. P., Sharples, K., Laking, G., & Helsby, N. A. (2016). High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy and Pharmacology, 77 (1), 195-204. 10.1007/s00280-015-2923-4
    URL: http://hdl.handle.net/2292/41465
    Other University of Auckland co-authors: Katie Burns, Michael Findlay, George Laking
  • Bull, M., Spicer, J., Huttunen, K., Denny, W., Ciccone, A., Browne, K., ... Helsby, N. (2015). The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents. European Journal of Drug Metabolism and Pharmacokinetics, 40 (4), 417-425. 10.1007/s13318-014-0220-y
    URL: http://hdl.handle.net/2292/32537
    Other University of Auckland co-authors: Bill Denny, Julie Spicer, Matthew Bull
  • Sullivan, J. A., Tong, J. L., Wong, M., Kumar, A., Sarkar, H., Ali, S., ... Helsby, N. A. (2015). Unravelling the role of SNM1 in the DNA repair system of Trypanosoma brucei. Molecular Microbiology, 96 (4), 827-838. 10.1111/mmi.12973
  • Sullivan, J. A., Tong, J. L., Wong, M., Kumar, A., Sarkar, H., Ali, S., ... Helsby, N. A. (2015). Unravelling the role of SNM1 in the DNA repair system of Trypanosoma brucei. Molecular Microbiology, 96 (4), 827-838. 10.1111/mmi.12973
  • Moriya, H., Saito, K., Helsby, N., Hayashi, N., Sugino, S., Yamakage, M., ... Kurosawa, N. (2014). Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects. Biomed Rep, 2 (2), 265-269. 10.3892/br.2013.210
  • Moriya, H., Saito, K., Helsby, N., Sugino, S., Yamakage, M., Sawaguchi, T., ... Kurosawa, N. (2014). Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers. Oncology Letters, 7 (6), 2035-2040. 10.3892/ol.2014.2046
  • Voak, A. A., Seifert, K., Helsby, N. A., & Wilkinson, S. R. (2014). Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs. Antimicrob Agents Chemother, 58 (1), 370-377. 10.1128/AAC.01459-13

Identifiers

Contact details

Primary office location

M&HS BUILDING 503 - Bldg 503
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links